Epitalon (Epithalon): The Complete Guide

Overview

Epitalon (also spelled Epithalon or Epithalone) is a synthetic tetrapeptide composed of four amino acids: alanine, glutamic acid, aspartic acid, and glycine (Ala-Glu-Asp-Gly). It was developed as a synthetic analog of epithalamin, a polypeptide extract derived from the bovine pineal gland. The peptide was designed and studied primarily by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia, beginning in the 1990s.

The central claim surrounding Epitalon is its reported ability to activate telomerase — the enzyme responsible for maintaining telomere length at the ends of chromosomes. Telomere shortening is a hallmark of cellular aging; each time a cell divides, its telomeres shorten slightly until they reach a critical length that triggers cell senescence or death. By reactivating telomerase in somatic cells, Epitalon is proposed to slow or partially reverse this aspect of cellular aging (Khavinson et al., 2003).

In addition to telomerase activation, Epitalon has been studied for its effects on the pineal gland and melatonin production. The pineal gland's melatonin output declines with age, and Epitalon has been reported to restore melatonin synthesis toward more youthful levels in aging animal models (Anisimov et al., 2003).

A critical consideration when evaluating Epitalon is the concentration of research within a single group. The overwhelming majority of published studies on Epitalon originate from Khavinson's laboratory or closely affiliated researchers. Independent replication by unaffiliated research groups is largely absent from the published literature. This does not invalidate the findings, but it significantly limits the confidence that can be placed in them. In mainstream biomedical research, independent replication is considered essential for establishing the validity of a claimed effect.

Epitalon has no FDA-approved indication. It has not entered the FDA clinical trial pathway. It is classified as a research chemical and is not approved for human therapeutic use by any major regulatory authority.

Quick Facts

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

Telomerase Activation

Telomeres are repetitive DNA sequences (TTAGGG in humans) that cap the ends of chromosomes, protecting genetic material from degradation during cell division. With each cell division, telomeres shorten. When they reach a critically short length, the cell enters senescence (permanent growth arrest) or undergoes apoptosis (programmed death). This process is considered a fundamental mechanism of biological aging.

Telomerase is a ribonucleoprotein enzyme that can add telomeric repeats back to chromosome ends, counteracting the shortening process. Telomerase is active in germ cells, stem cells, and most cancer cells, but is largely inactive in normal somatic (body) cells. The reactivation of telomerase in somatic cells has been a focus of aging research for decades.

Khavinson and colleagues reported that Epitalon activates the catalytic subunit of telomerase (hTERT) in human somatic cells in vitro, leading to elongation of telomeres and extension of cell lifespan beyond the normal Hayflick limit (Khavinson et al., 2003). In cell culture studies using human fetal fibroblasts and adult retinal pigment epithelial cells, Epitalon-treated cells reportedly underwent additional population doublings compared to untreated controls (Anisimov et al., 2003).

The specific molecular pathway by which a four-amino-acid peptide activates telomerase gene expression has not been fully elucidated. Khavinson has proposed that short peptides can interact directly with DNA through sequence-specific binding, potentially influencing gene transcription — a concept termed "peptide bioregulation" (Khavinson, 2009). This hypothesis remains outside the mainstream of molecular biology and has not been independently validated.

Pineal Gland and Melatonin Regulation

Epitalon was originally developed from epithalamin, an extract of the pineal gland. The pineal gland produces melatonin, the hormone primarily responsible for circadian rhythm regulation. Melatonin production declines with age — a process associated with disrupted sleep patterns, reduced antioxidant capacity, and altered immune function in older adults.

In aging rat models, Epitalon has been reported to:

• Restore the nighttime peak of melatonin production toward levels observed in younger animals (Anisimov et al., 2003)
• Normalize the circadian rhythm of cortisol secretion (Khavinson et al., 2003)
• Influence the expression of genes involved in melatonin synthesis in pinealocytes

One small human study in elderly patients reported that Epitalon administration restored evening melatonin levels, though this study was conducted without a placebo control group and involved a limited number of participants (Korkushko et al., 2004).

Neuroendocrine and Immune Modulation

Studies from the Khavinson group have reported broader neuroendocrine effects of Epitalon, including:

• Modulation of hypothalamic-pituitary axis function in aging animals
• Restoration of thymic function and T-cell immunity in aged rodents (Anisimov et al., 2003)
• Antioxidant effects through increased activity of superoxide dismutase (SOD) and other antioxidant enzymes
• Reported anti-tumor effects in some rodent models, possibly related to enhanced immune surveillance (Anisimov et al., 2001)

These reported effects are broad and, if confirmed, would represent a wide-ranging neuroendocrine intervention. However, the mechanisms connecting a simple tetrapeptide to such diverse systemic effects remain unclear, and the absence of independent replication limits interpretation.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

Telomerase and Telomere Studies

• Cell culture — fibroblasts: Epitalon activated telomerase and induced telomere elongation in human fetal lung fibroblasts, extending their replicative lifespan by 10 additional population doublings compared to controls (Khavinson et al., 2003).
• Cell culture — retinal pigment epithelium: In human retinal pigment epithelial cells (a non-dividing, differentiated cell type), Epitalon reportedly activated telomerase and promoted cell division that would not normally occur, suggesting reactivation of proliferative capacity (Khavinson et al., 2003).
• In vivo telomere effects: A study in aging mice reported that Epitalon treatment increased telomerase activity in brain, liver, and other tissues, with corresponding preservation of telomere length compared to untreated controls (Khavinson, 2009).

Lifespan Studies in Animals

• Rodent lifespan: Several studies by the Anisimov-Khavinson group reported that Epitalon extended mean and maximum lifespan in mice and rats. In one study using female CBA mice, treatment with Epitalon increased mean lifespan by approximately 12% and maximum lifespan by approximately 10% (Anisimov et al., 2003).
• Tumor incidence: Epitalon-treated mice in some studies showed reduced spontaneous tumor development compared to controls, potentially related to improved immune surveillance or telomere maintenance (Anisimov et al., 2001).
• Drosophila studies: One study reported lifespan extension in fruit flies treated with Epitalon, though the relevance of Drosophila telomere biology (which differs from mammalian biology) limits interpretation (Anisimov et al., 2003).

Melatonin and Pineal Gland Studies

• Aging rats: Epitalon restored the nocturnal melatonin peak in aged rats to levels comparable to younger animals. The effect was accompanied by improved circadian rhythm regularity (Anisimov et al., 2003).
• Human study — elderly patients: A small study in elderly participants (n=14) reported that a course of Epitalon restored evening melatonin secretion. This study lacked a placebo control group and was not randomized or blinded (Korkushko et al., 2004).

Immune Function Studies

• Thymic restoration: In aged rats, Epitalon reportedly promoted partial restoration of thymic structure and function, with increased T-cell proliferation and immune responsiveness (Anisimov et al., 2003).
• Cytokine modulation: Some studies report normalization of cytokine profiles in aged animals treated with Epitalon, though specific immune parameters varied across studies.

Retinal Studies

• Retinitis pigmentosa model: Khavinson and colleagues reported that Epitalon preserved retinal function in a rat model of retinitis pigmentosa, maintaining electroretinogram responses in treated animals while untreated controls showed progressive deterioration (Anisimov et al., 2003).

Human Studies

Published human data on Epitalon is extremely limited:

• Epithalamin studies (the precursor extract): Khavinson conducted studies using epithalamin (the crude pineal extract from which Epitalon was derived) in elderly patients in Russia. These studies, conducted over several years, reported reduced cardiovascular mortality and improved biomarkers of aging in treated groups (Korkushko et al., 2004). However, these studies used the extract (epithalamin), not the synthetic peptide (Epitalon) specifically, and were not conducted under Western clinical trial standards (no registered protocol, limited blinding, no independent monitoring).
• Epitalon-specific human data: Small, uncontrolled observational studies have been reported in Russian-language publications, with claims of improved melatonin levels, sleep quality, and subjective well-being. These have not been published in indexed, peer-reviewed Western journals with full methodology.

Limitations of the Research

• Single research group: The vast majority of Epitalon studies originate from the Khavinson laboratory or close collaborators. Independent replication is the cornerstone of scientific validation, and its absence is a significant limitation.
• No Western clinical trials: Epitalon has not entered the FDA Investigational New Drug (IND) pathway and has not been studied in registered, monitored clinical trials under ICH-GCP standards.
• Publication in lower-impact journals: Many Epitalon studies are published in journals with limited peer review rigor or in Russian-language publications not indexed in major databases.
• Mechanistic gap: How a simple tetrapeptide produces such diverse biological effects is not well explained by established molecular biology. The proposed "peptide bioregulation" framework has not been adopted by the broader research community.
• Potential conflicts of interest: Khavinson has commercial interests in peptide bioregulators and holds patents related to these compounds, which represents a potential conflict of interest in evaluating the research objectively.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA Status

Epitalon has no FDA-approved indication. It has not been submitted for FDA review, has not completed any phase of the FDA clinical trial process, and is not classified as a drug, dietary supplement, or approved biologic. Any use is considered experimental.

How It Has Been Accessed

• Research chemical suppliers: Epitalon is primarily available through research chemical vendors, sold labeled "for research purposes only" or "not for human consumption." This is the most common source.
• Anti-aging clinics: Some longevity and anti-aging clinics, particularly outside the United States, have offered Epitalon as part of anti-aging protocols. These are not regulated therapeutic programs in most jurisdictions.
• International sources: Epitalon has been available through Russian and Eastern European suppliers, where regulatory frameworks differ from FDA standards.

Claimed Applications

The following applications are described in the research literature from the Khavinson group and in anti-aging clinical practice. They are not FDA-approved indications and are not supported by Phase 2/3 clinical trial data.

What Epitalon Is NOT Used For

• Cancer treatment: While some rodent studies reported reduced tumor incidence, Epitalon is not a cancer treatment. Its effects on telomerase raise theoretical concerns about promoting cancer cell proliferation, as telomerase activation is a hallmark of malignant cells.
• Acute medical conditions: Epitalon is positioned in the longevity/anti-aging space, not as a treatment for acute illness or injury.
• Performance enhancement: Epitalon is not an anabolic or performance-enhancing substance.
• Replacement for established treatments: Epitalon should not be used as a substitute for evidence-based medical interventions for any condition.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

Commonly Reported Protocols

Dosing protocols above are derived from published research by the Khavinson group and reported anti-aging clinical practice — not from FDA-approved labeling. Key references: Khavinson et al., 2003 (Bulletin of Experimental Biology and Medicine) · Anisimov et al., 2003 (Biogerontology) · Khavinson, 2009 (Peptides)

Cycling Patterns

Epitalon is typically administered in short, discrete cycles rather than continuously. Commonly reported patterns include:

• Twice yearly: One 10–20 day cycle every 6 months. The most common maintenance schedule reported in anti-aging practice.
• Three times yearly: One 10–20 day cycle every 4 months. Used by practitioners who favor more frequent intervention.
• Annual course: A single 20-day cycle once per year. Conservative approach for long-term use.

The rationale for cyclical rather than continuous dosing is based on the hypothesis that Epitalon triggers a biological response (telomerase activation, melatonin cycle restoration) that persists beyond the administration period. This hypothesis has not been rigorously tested in dose-duration studies.

Administration

Epitalon for subcutaneous administration is typically supplied as a lyophilized (freeze-dried) powder that requires reconstitution with bacteriostatic water before use. Preparation and administration technique should be demonstrated and supervised by a qualified healthcare provider. Do not attempt to reconstitute or administer any peptide without proper medical guidance.

Storage

• Lyophilized (unreconstituted) powder: Store refrigerated (2–8°C / 36–46°F). Stable for months when kept dry and cold. Some suppliers recommend freezer storage for long-term stability.
• Reconstituted solution: Refrigerate and use within 2–3 weeks. Do not freeze reconstituted peptide. Discard if solution becomes cloudy or discolored.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What Users Report

Reported Timeline

Commonly Reported Effects

• Sleep improvement: The most consistently reported effect. Users describe falling asleep faster, sleeping more deeply, and waking more refreshed.
• Energy and alertness: Improved daytime energy, often attributed to better sleep quality.
• Skin appearance: Some users report improved skin texture, reduced dryness, and a "healthier" appearance. These reports are subjective and uncontrolled.
• General well-being: A diffuse sense of improved vitality and health. This is a common report with many anti-aging interventions and is highly susceptible to placebo effect.
• Cognitive function: Some users report improved mental clarity and focus, though no cognitive testing has been performed in controlled studies.

What "Results" Means Without Controlled Data

Interpreting user reports for Epitalon requires particular caution:

• Strong expectation bias: Users who invest in an anti-aging peptide typically have strong expectations of benefit, which amplifies placebo response.
• Subjective endpoints: Sleep quality, energy, skin appearance, and well-being are highly subjective measures that are susceptible to reporting bias.
• No biomarker confirmation: Users do not typically measure telomere length, telomerase activity, or melatonin levels before and after treatment, making it impossible to connect subjective reports to the proposed mechanism.
• Selection bias: Individuals who report positive experiences are overrepresented in online forums and reviews.
• Cost justification: Users who have paid for a product are psychologically motivated to perceive benefit (cognitive dissonance reduction).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Reported Side Effects

Note: These rates are based on limited clinical reports and user accounts — not from large controlled trials. True incidence rates in humans have not been established.

Animal Toxicology Data

In the published animal studies from the Khavinson group, Epitalon has been described as non-toxic at the doses studied. No lethal dose has been reported, and chronic administration studies in rodents did not document organ toxicity (Anisimov et al., 2003). However, these studies were conducted by the group that developed the peptide, and independent toxicology studies have not been published.

Theoretical Risks and Concerns

• Telomerase activation and cancer: Telomerase activation is a hallmark of cancer cells — it allows them to divide indefinitely. While some Khavinson studies reported reduced tumor incidence, the theoretical concern that exogenous telomerase activation could promote or sustain existing malignancies has not been adequately addressed. Individuals with active cancer, a recent cancer history, or known cancer predisposition genes should exercise particular caution.
• Unknown long-term effects: No long-term human safety data exists for Epitalon. The consequences of periodic telomerase activation in humans over years or decades are entirely unknown.
• Single-source safety data: All safety data originates from the same research group that developed and has commercial interests in the compound. Independent safety evaluation has not been performed.
• Product purity concerns: Research chemical-grade Epitalon may contain impurities, degradation products, or incorrect peptide content. Adverse effects from contaminants would not be attributable to Epitalon itself.
• Hormonal effects: Epitalon's reported effects on the pineal gland and neuroendocrine axis could theoretically interact with hormonal balance, particularly in individuals taking hormone replacement therapy or medications affecting the hypothalamic-pituitary axis.

Drug Interactions

No formal drug interaction studies have been conducted with Epitalon. Theoretical interactions include:

• Melatonin supplements: Additive effects on melatonin pathways. Concurrent use may produce excessive sedation.
• Immunosuppressants: Epitalon's reported immune-stimulating effects could theoretically counteract immunosuppressive therapy.
• Hormone replacement therapy: Potential interactions with neuroendocrine modulation.
• Sedatives and sleep medications: Possible additive sedation via melatonin pathway enhancement.

Contraindications

• Active cancer or recent cancer history — due to telomerase activation concerns
• Known cancer predisposition syndromes — theoretical increased risk
• Pregnancy and breastfeeding — no safety data available
• Children — no pediatric data available
• Autoimmune conditions — potential immune modulation effects are unpredictable

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

FDA Status

Epitalon has no FDA classification — it has not been submitted for evaluation as a drug, biologic, or compounding ingredient. Unlike some peptides that have been specifically addressed by the FDA (e.g., BPC-157's Category 2 classification), Epitalon has not been the subject of FDA regulatory action because it has never entered the FDA pathway.

This means:

• It is not FDA-approved for any indication
• It has not been evaluated by the FDA for safety, efficacy, or quality
• It is not listed on the FDA's bulk drug substance evaluation lists (Category 1, 2, or 3)
• Compounding pharmacies have not commonly produced Epitalon preparations, as it lacks the clinical demand and evidence base that drove BPC-157 compounding

Research Chemical Classification

Epitalon is sold primarily as a "research chemical" or "reference standard" by peptide synthesis companies. This classification:

• Means the product is labeled "not for human consumption" or "for research purposes only"
• Places it outside FDA drug manufacturing oversight
• Does not require cGMP manufacturing, batch testing, or purity verification
• Allows legal sale and purchase in most jurisdictions, as the substance is not a controlled or scheduled compound

WADA Status

Epitalon falls under WADA's Section S0 (Non-Approved Substances) as a pharmacological substance without regulatory approval for human therapeutic use. Athletes subject to anti-doping testing should treat Epitalon as a prohibited substance.

Status in Russia

The regulatory context for Epitalon in Russia is distinct from Western regulatory frameworks. Khavinson's peptide bioregulators have been registered and used in Russian clinical practice under the Russian regulatory system. However, Russian drug approval standards and processes differ significantly from FDA, EMA, and ICH-GCP frameworks, and approval in Russia is not recognized by Western regulatory authorities.

International Status

Epitalon is not approved for therapeutic use in any major Western regulatory jurisdiction (FDA, EMA, MHRA, TGA, Health Canada). It is generally not a controlled substance internationally, meaning it can be legally purchased and possessed in most countries as a research chemical. Regulatory treatment varies by jurisdiction.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Typical Pricing

Cost Per Cycle

Insurance Coverage

Epitalon is not covered by any insurance plan. It has no FDA-approved indication, is not classified as a drug, and cannot be billed under any prescription or medical benefit. All costs are out-of-pocket.

Factors Affecting Cost

• Source quality: Research chemical suppliers vary widely in pricing and quality. Cheaper products may have lower purity or incorrect peptide content.
• Dosing protocol: Higher doses and longer cycles cost proportionally more.
• Clinical supervision: Clinic-based administration includes provider fees, which increase total cost but provide medical oversight.
• Testing: Independent third-party purity testing (if desired) adds additional cost ($50–$200 per sample).

Cost Comparison: Epitalon vs. Related Anti-Aging Interventions

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Myth: Epitalon reverses aging.

Answer: Aging is a multi-factorial process involving telomere shortening, mitochondrial dysfunction, epigenetic changes, stem cell exhaustion, proteostatic decline, and numerous other mechanisms. Telomerase activation — even if confirmed in humans — would address only one of these pathways. No single intervention has been shown to "reverse aging" in humans. Epitalon has shown telomerase activation in cell culture and lifespan extension in rodent models from a single research group (Khavinson et al., 2003). This is not the same as reversing the aging process in humans.

Myth: Epitalon is clinically proven.

Answer: Epitalon has not been evaluated in Phase 2 or Phase 3 clinical trials under Western regulatory standards (ICH-GCP). The human data that exists consists of small, uncontrolled observational studies conducted primarily in Russia without registered protocols, independent monitoring, or adequate blinding (Korkushko et al., 2004). "Clinically proven" requires randomized, double-blind, placebo-controlled trials with adequate sample sizes — none of which exist for Epitalon.

Myth: Epitalon is the same as melatonin.

Answer: Epitalon is a tetrapeptide that reportedly stimulates the pineal gland to produce melatonin — it is not melatonin itself. Melatonin is a hormone (N-acetyl-5-methoxytryptamine) that directly acts on melatonin receptors. Epitalon's proposed mechanism is indirect: by modulating pineal gland function, it reportedly increases the body's own melatonin production (Anisimov et al., 2003). These are fundamentally different interventions, even if some downstream effects may overlap.

Myth: Epitalon causes cancer because it activates telomerase.

Answer: The relationship between telomerase and cancer is more nuanced than this claim suggests. Telomerase activation is indeed a hallmark of cancer cells, as it allows them to bypass the normal limit on cell division. However, telomerase activation alone is not sufficient to cause cancer — multiple oncogenic mutations are required for malignant transformation. In the Khavinson studies, Epitalon-treated animals showed reduced tumor incidence, not increased (Anisimov et al., 2001). That said, the theoretical concern remains biologically plausible, particularly for individuals with pre-existing malignancies or cancer predisposition. The question has not been adequately studied in humans.

Myth: All peptide bioregulators work the same way.

Answer: Khavinson has developed dozens of short peptide "bioregulators" targeting different organs and systems (e.g., Vilon for immune, Cortagen for brain, Livagen for liver, Epitalon for pineal). Each is a different amino acid sequence proposed to interact with different gene targets. The evidence base, mechanisms, and clinical data vary for each peptide. Grouping them together as interchangeable is inaccurate.

Myth: Research from a single group means the data is fraudulent.

Answer: Single-group research concentration is a limitation, not evidence of fraud. Many legitimate areas of research begin with a single pioneering group before attracting independent investigators. However, the absence of independent replication after more than two decades of publication is unusual and does warrant caution. The appropriate response is to treat the data as preliminary and promising rather than established — not to assume fraud without evidence of fabrication.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence:

• Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed as an analog of the bovine pineal gland extract epithalamin. It has been studied primarily for telomerase activation, melatonin restoration, and anti-aging effects.
• The evidence base comes almost entirely from a single research group — Vladimir Khavinson and colleagues in Saint Petersburg, Russia. Independent replication by unaffiliated researchers is largely absent. This is the most significant limitation of the Epitalon evidence base.
• Preclinical data shows telomerase activation in cell culture, lifespan extension in rodent models, melatonin restoration in aging animals, and immune function improvements. These are published findings, but their validity is limited by the lack of independent confirmation.
• Human data is extremely limited — small, uncontrolled studies without registered protocols or independent monitoring. No Phase 2 or Phase 3 clinical trials have been conducted under Western regulatory standards.
• It is not FDA-approved for any indication and has not entered the FDA regulatory pathway. It is classified as a research chemical and is available primarily through research suppliers and some anti-aging clinics.
• The safety profile appears favorable in the limited available data, but the absence of large-scale human safety studies means that rare or long-term risks — including the theoretical concern about telomerase activation and cancer — have not been adequately characterized.
• Common protocols involve 5–10 mg subcutaneously daily for 10–20 day cycles, repeated 2–3 times per year. Cost ranges from $100–$300 per month of active use, with annualized costs of $100–$1,500 depending on protocol. Insurance does not cover it.
• Product quality is a significant concern in the research chemical market, with no regulatory oversight for purity, potency, or manufacturing standards.

Questions to Ask a Provider

• What is the evidence base for Epitalon in my specific situation, and how does it compare to established interventions?
• Are you aware that the research comes primarily from a single laboratory group without independent replication?
• What is the source of the Epitalon, and has it been independently tested for purity and identity?
• What monitoring or biomarkers (telomere length, melatonin levels) will be tracked to assess response?
• What are the realistic expectations, and how do we differentiate actual effects from placebo response?
• Given my medical history, are there any specific risks — particularly related to telomerase activation?
• What evidence-based anti-aging or longevity interventions should I consider first or alongside Epitalon?

Sources & Further Reading

Telomerase and Cellular Aging

• Khavinson VKh, Bondarev IE, Butyugov AA (2003) — "Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells" — Bulletin of Experimental Biology and Medicine
• Khavinson VKh (2009) — "Peptides and ageing" — Neuroendocrinology Letters

Lifespan and Biomarker Studies

• Anisimov VN, Khavinson VKh, Popovich IG et al. (2003) — "Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice" — Biogerontology
• Anisimov VN, Khavinson VKh et al. (2001) — "Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice" — International Journal of Cancer

Melatonin and Pineal Gland

• Korkushko OV, Khavinson VKh, Shatilo VB, Magdich LV (2004) — "Effect of peptide preparation epithalamin on circadian rhythm of melatonin secretion in elderly people" — Bulletin of Experimental Biology and Medicine
• Anisimov VN et al. (2003) — Melatonin restoration in aging animal models

Immune Function

• Anisimov VN et al. (2003) — Thymic restoration and immune effects in aging animals

Peptide Bioregulation (Theoretical Framework)

• Khavinson VKh (2009) — "Peptides and ageing" — review of the peptide bioregulation hypothesis

Regulatory References

• FDA: Bulk Drug Substances Used in Compounding
• WADA: Prohibited List (current year)

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.